UGT2B15 and breast carcinoma: The polymorphisms of CYP3A5 (CYP3A5*1 and *3), CYP2D6 (CYP2D6*1 and *4), SULT1A1 (SULT1A1*1 and *2) and UGT2B15 (UGT2B15*1 and *2) were examined in tamoxifen-treated postmenopausal patients with breast cancer, to discern whether the genotypes correlated with clinical/pathological factors and/or to the benefit of tamoxifen.